These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30655255)

  • 1. Brain DSC MR Perfusion in Children: A Clinical Feasibility Study Using Different Technical Standards of Contrast Administration.
    Gaudino S; Martucci M; Botto A; Ruberto E; Leone E; Infante A; Ramaglia A; Caldarelli M; Frassanito P; Triulzi FM; Colosimo C
    AJNR Am J Neuroradiol; 2019 Feb; 40(2):359-365. PubMed ID: 30655255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic susceptibility MR perfusion imaging of the brain: not a question of contrast agent molarity.
    Panara V; Chiacchiaretta P; Rapino M; Maruotti V; Parenti M; Piccirilli E; Pizzi AD; Caulo M
    Neuroradiology; 2022 Apr; 64(4):685-692. PubMed ID: 34557937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter-individual Comparison of Gadobutrol and Gadoteridol Tissue Time-intensity Profiles for Dynamic Susceptibility Contrast Perfusion MR Imaging.
    Yamada M; Taoka T; Kawaguchi A; Yasuda K; Niinomi Y; Ohashi Y; Okuda T; Naganawa S
    Magn Reson Med Sci; 2019 Jan; 18(1):75-81. PubMed ID: 29794406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors.
    Schmainda KM; Prah MA; Hu LS; Quarles CC; Semmineh N; Rand SD; Connelly JM; Anderies B; Zhou Y; Liu Y; Logan B; Stokes A; Baird G; Boxerman JL
    AJNR Am J Neuroradiol; 2019 Apr; 40(4):626-633. PubMed ID: 30923088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol.
    Tombach B; Benner T; Reimer P; Schuierer G; Fallenberg EM; Geens V; Wels T; Sorensen AG
    Radiology; 2003 Mar; 226(3):880-8. PubMed ID: 12601217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of a high relaxivity contrast agent administered at half dose in dynamic susceptibility contrast MRI of brain gliomas.
    Crisi G; Filice S; Erb G; Bozzetti F
    J Magn Reson Imaging; 2017 Feb; 45(2):500-506. PubMed ID: 27373976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Susceptibility Artifacts on Perfusion MRI in Patients with Primary Brain Tumor: A Comparison of Arterial Spin-Labeling versus DSC.
    Maral H; Ertekin E; Tunçyürek Ö; Özsunar Y
    AJNR Am J Neuroradiol; 2020 Feb; 41(2):255-261. PubMed ID: 31974077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T.
    Essig M; Lodemann KP; Le-Huu M; Brüning R; Kirchin M; Reith W
    Invest Radiol; 2006 Mar; 41(3):256-63. PubMed ID: 16481908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian estimation of cerebral perfusion using reduced-contrast-dose dynamic susceptibility contrast perfusion at 3T.
    Nael K; Mossadeghi B; Boutelier T; Kubal W; Krupinski EA; Dagher J; Villablanca JP
    AJNR Am J Neuroradiol; 2015 Apr; 36(4):710-8. PubMed ID: 25430859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Administrations of Gadobutrol in the Pediatric Brain: No Change in T1 Signal at MRI.
    Bhargava R; Persad ARL; Bhargava NK; Hawkes M
    Radiology; 2018 Oct; 289(1):204-209. PubMed ID: 29944079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-dimensional dynamic susceptibility-weighted perfusion MR imaging at 3.0 T: feasibility and contrast agent dose.
    Manka C; Träber F; Gieseke J; Schild HH; Kuhl CK
    Radiology; 2005 Mar; 234(3):869-77. PubMed ID: 15665227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of gadobutrol in more than 1,000 pediatric patients: subanalysis of the GARDIAN study, a global multicenter prospective non-interventional study.
    Glutig K; Bhargava R; Hahn G; Hirsch W; Kunze C; Mentzel HJ; Schaefer JF; Willinek W; Palkowitsch P;
    Pediatr Radiol; 2016 Aug; 46(9):1317-23. PubMed ID: 27041276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of BOLD cerebrovascular reactivity mapping and DSC MR perfusion imaging for prediction of neurovascular uncoupling potential in brain tumors.
    Pillai JJ; Zacà D
    Technol Cancer Res Treat; 2012 Aug; 11(4):361-74. PubMed ID: 22376130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images.
    Anzalone N; Castellano A; Cadioli M; Conte GM; Cuccarini V; Bizzi A; Grimaldi M; Costa A; Grillea G; Vitali P; Aquino D; Terreni MR; Torri V; Erickson BJ; Caulo M
    Radiology; 2018 Jun; 287(3):933-943. PubMed ID: 29361245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wavelet-based reconstruction of dynamic susceptibility MR-perfusion: a new method to visualize hypervascular brain tumors.
    Huber T; Rotkopf L; Wiestler B; Kunz WG; Bette S; Gempt J; Preibisch C; Ricke J; Zimmer C; Kirschke JS; Sommer WH; Thierfelder KM
    Eur Radiol; 2019 May; 29(5):2669-2676. PubMed ID: 30552476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrathecal Use of Gadobutrol for Glymphatic MR Imaging: Prospective Safety Study of 100 Patients.
    Edeklev CS; Halvorsen M; Løvland G; Vatnehol SAS; Gjertsen Ø; Nedregaard B; Sletteberg R; Ringstad G; Eide PK
    AJNR Am J Neuroradiol; 2019 Aug; 40(8):1257-1264. PubMed ID: 31320462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of quantitative dynamic susceptibility-contrast MRI perfusion estimates obtained using different contrast-agent administration schemes at 3T.
    Wirestam R; Thilmann O; Knutsson L; Björkman-Burtscher IM; Larsson EM; Ståhlberg F
    Eur J Radiol; 2010 Jul; 75(1):e86-91. PubMed ID: 19720489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T.
    Morelli JN; Runge VM; Vu L; Loynachan AT; Attenberger UI
    Invest Radiol; 2010 Dec; 45(12):810-8. PubMed ID: 20856127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T.
    Thilmann O; Larsson EM; Björkman-Burtscher IM; Ståhlberg F; Wirestam R
    J Magn Reson Imaging; 2005 Nov; 22(5):597-604. PubMed ID: 16200539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadolinium deposition within the paediatric brain: no increased intrinsic T1-weighted signal intensity within the dentate nucleus following the administration of a minimum of four doses of the macrocyclic agent gadobutrol.
    Young JR; Qiao J; Orosz I; Salamon N; Franke MA; Kim HJ; Pope WB
    Eur Radiol; 2018 Nov; 28(11):4882-4889. PubMed ID: 29744642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.